LifeStance Health Group, Inc.
LifeStance provides outpatient mental healthcare through clinicians employed by its subsidiaries and supported practices. Patients receive care virtually or in person at its centers, and services include psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. Its clinicians include psychiatrists, advanced practice nurses, psychologists and therapists, and treat children, adolescents, adults and geriatrics. LifeStance also works with payors and physician groups to connect patients with in-network care and referrals. As of December 31, 2025, it employed 8,040 licensed mental health clinicians in 33 states and operated 572 centers. LifeStance earns revenue mainly on a per-visit basis for patient care, generally through fee-for-service reimbursement from in-network payors. For supported practices, it receives management fees under long-term management services contracts. Its headquarters are in Scottsdale, Arizona.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LFST in the last 30 days.
See all $LFST insider activity →Canaccord Genuity reaffirmed its Buy rating on LifeStance Health Gr and increased its price target to $16 from $15, suggesting a 19.1% upside from the Nov 5 close of $13.43.
Keybanc kept LifeStance Health Gr's rating at Overweight and increased its price target to $17 from $15, suggesting a 26.6% upside from the Nov 5 close of $13.43, according to the firm.
LifeStance Health Group (LFST) forecasted Q4 revenue of $446M-$466M and adjusted EBITDA of $56M-$64M. The company expects a 1-2% reduction in 2027 revenue growth due to a new electronic health record system. LifeStance expanded specialty services, including TMS and SPRAVATO, and plans to continue acquisitions and center openings. Management expects specialty services revenue to reach $70M this year, up from $50M in 2025.
Over the past 7 days, AlphAI's AI scored 13 news stories mentioning LFST (LifeStance Health Group, Inc.). Coverage has skewed bullish: 9 bullish, 2 neutral, and 2 bearish.
Recent LFST coverage spans earnings, financial news and corporate actions.
Analyst upgrade may generate modest buying interest.
Keybanc kept LifeStance Health Gr's rating at Overweight and increased its price target to $17 from $15, suggesting a 26.6% upside from the Nov 5 close of $13.43, according to the firm.
Guidance below prior expectations may weigh on the stock.
Strong earnings and guidance boost sentiment.
Guidance raise and strong earnings suggest upside momentum.
AlphAI scores every news story that mentions LFST with an AI model for sentiment and relevance, and aggregates insider trades from LifeStance Health Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Canaccord Genuity reaffirmed its Buy rating on LifeStance Health Gr and increased its price target to $16 from $15, suggesting a 19.1% upside from the Nov 5 close of $13.43.
Keybanc kept LifeStance Health Gr's rating at Overweight and increased its price target to $17 from $15, suggesting a 26.6% upside from the Nov 5 close of $13.43, according to the firm.
LifeStance Health Group (LFST) forecasted Q4 revenue of $446M-$466M and adjusted EBITDA of $56M-$64M. The company expects a 1-2% reduction in 2027 revenue growth due to a new electronic health record system. LifeStance expanded specialty services, including TMS and SPRAVATO, and plans to continue acquisitions and center openings. Management expects specialty services revenue to reach $70M this year, up from $50M in 2025.
Oscar Health (OSCR) and LifeStance Health (LFST) reported Q3 earnings above estimates and raised outlooks. LFST shares rose pre-market, while OSCR gave up early gains. Both stocks rose after the Democratic Congress victory. Analysts anticipate political shifts may impact the sector.
LifeStance Health Group reported Q3 2026 revenue of $455.9 million, up 25% YoY, with visits reaching 2.7 million, a 17% increase. Net income rose to $22.4 million from $1.1 million, and adjusted EBITDA grew 70% to $68.4 million. The company raised full-year revenue guidance to $1.741-$1.761 billion and adjusted EBITDA to $242-$250 million.
LifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor Relations Contact Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook SCOTTSDALE, Ariz. – November 5, 2026 – LifeStance
LifeStance Health reported that patients with treatment-resistant depression showed clinically meaningful improvements in symptoms after esketamine or TMS treatments. 74% of esketamine patients and 61% of TMS patients saw reduced depression severity. Suicidal ideation also decreased significantly. The company is expanding access to these treatments. LifeStance serves over one million patients annually and is listed on Nasdaq as LFST.
Teresa DeLuca, M.D., will resign from LifeStance Health's board and committees by December 31, 2026. The company stated the resignation is not due to any disagreement. No replacement details were disclosed.
LifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 14, 2026, Teresa DeLuca, M.D., notified the LifeStance Health Group, Inc. (the “Company”) board of directors (th
LifeStance Health Group (LFST) will release its Q3 2026 earnings on Nov. 5 before market open and host a conference call at 8:30 a.m. ET. The company is a major provider of outpatient mental healthcare with over 8,500 employees across 35 states.
